Prasugrel, a third generation thienopyridine and potent platelet inhibitor.

Journal Article (Review)

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

Full Text

Duke Authors

Cited Authors

  • Gurbel, PA; Tantry, US

Published Date

  • March 2008

Published In

Volume / Issue

  • 9 / 3

Start / End Page

  • 324 - 336

PubMed ID

  • 18311669

International Standard Serial Number (ISSN)

  • 1472-4472

Language

  • eng

Conference Location

  • England